Bitter taste receptors are expressed in human epithelial ovarian and prostate cancers cells and noscapine stimulation impacts cell survival
Bitter taste receptors (Tas2Rs) are a subfamily of G-protein coupled receptors expressed not only in the oral cavity but also in several extra-oral tissues and disease states. Several natural bitter compounds from plants, such as bitter melon extract and noscapine, have displayed anti-cancer effects against various cancer types. In this study, we examined the prevalence of Tas2R subtype expression in several epithelial ovarian or prostate cancer cell lines, and the functionality of Tas2R14 was determined. qPCR analysis of five TAS2Rs demonstrated that mRNA expression often varies greatly in cancer cells in comparison to normal tissue. Using receptor-specific siRNAs, we also demonstrated that noscapine stimulation of ovarian cancer cells increased apoptosis in ovarian cancer cells in a receptor-dependent, but ROS-independent manner. This study furthers our understanding of the function of Tas2Rs in ovarian cancer by demonstrating that their activation has an impact on cell survival.
KeywordsApoptosis Bitter taste receptor Epithelial ovarian cancer Prostate cancer Noscapine G protein coupled receptor
This work was supported by Grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) (Grant RGPIN-355310-2013) and seed funding from the Beatrice Hunter Cancer Research Institute (BHCRI) (to DJD), a Bridge Grant from BHCRI (to GD), and a CancerCare Manitoba Foundation grant (to MWN). LTPM is supported through a Canadian Graduate Scholarship from the Canadian Institutes of Health Research and is a trainee in the Cancer Research Training Program of the BHCRI, with funds provided by Motorcycle Ride for Dad—Nova Scotia Chapter. JS was supported by a postdoctoral fellowship from the BHCRI.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to declare.
- 4.Deloose E, Janssen P, Corsetti M, Biesiekierski J, Masuy I, Rotondo A, Van Oudenhove L, Depoortere I, Tack J (2017) Intragastric infusion of denatonium benzoate attenuates interdigestive gastric motility and hunger scores in healthy female volunteers. Am J Clin Nutr 105:580–588. https://doi.org/10.3945/ajcn.116.138297 CrossRefGoogle Scholar
- 5.Foster SR, Porrello ER, Purdue B, Chan HW, Voigt A, Frenzel S, Hannan RD, Moritz KM, Simmons DG, Molenaar P, Roura E, Boehm U, Meyerhof W, Thomas WG (2013) Expression, regulation and putative nutrient-sensing function of taste GPCRs in the heart. PLoS ONE 8:e64579. https://doi.org/10.1371/journal.pone.0064579 CrossRefGoogle Scholar
- 10.Garcia-Esparcia P, Schluter A, Carmona M, Moreno J, Ansoleaga B, Torrejon-Escribano B, Gustincich S, Pujol A, Ferrer I (2013) Functional genomics reveals dysregulation of cortical olfactory receptors in Parkinson disease: novel putative chemoreceptors in the human brain. J Neuropathol Exp Neurol 72:524–539. https://doi.org/10.1097/NEN.0b013e318294fd76 CrossRefGoogle Scholar
- 13.Gaida MM, Mayer C, Dapunt U, Stegmaier S, Schirmacher P, Wabnitz GH, Hansch GM (2016) Expression of the bitter receptor T2R38 in pancreatic cancer: localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Oncotarget 7:12623–12632. https://doi.org/10.18632/oncotarget.7206 CrossRefGoogle Scholar
- 17.Yung MM, Ross FA, Hardie DG, Leung TH, Zhan J, Ngan HY, Chan DW (2016) Bitter Melon (Momordica charantia) extract inhibits tumorigenicity and overcomes cisplatin-resistance in ovarian cancer cells through targeting AMPK signaling cascade. Integr Cancer Ther 15:376–389. https://doi.org/10.1177/1534735415611747 CrossRefGoogle Scholar
- 18.Kwatra D, Subramaniam D, Ramamoorthy P, Standing D, Moran E, Velayutham R, Mitra A, Umar S, Anant S (2013) Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid Based Complement Alternat Med 2013:702869. https://doi.org/10.1155/2013/702869 CrossRefGoogle Scholar
- 22.Shen W, Liang B, Yin J, Li X, Cheng J (2015) noscapine increases the sensitivity of drug-resistant ovarian cancer cell line SKOV3/DDP to cisplatin by regulating cell cycle and activating apoptotic pathways. Cell Biochem Biophys 72:203–213. https://doi.org/10.1007/s12013-014-0438-y CrossRefGoogle Scholar
- 23.Barken I, Geller J, Rogosnitzky M (2008) Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res 28:3701–3704Google Scholar
- 31.Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668–679. https://doi.org/10.1038/nrc4019 CrossRefGoogle Scholar
- 40.Carrai M, Steinke V, Vodicka P, Pardini B, Rahner N, Holinski-Feder E, Morak M, Schackert HK, Gorgens H, Stemmler S, Betz B, Kloor M, Engel C, Buttner R, Naccarati A, Vodickova L, Novotny J, Stein A, Hemminki K, Propping P, Forsti A, Canzian F, Barale R, Campa D (2011) Association between TAS2R38 gene polymorphisms and colorectal cancer risk: a case-control study in two independent populations of Caucasian origin. PLoS One 6:e20464. https://doi.org/10.1371/journal.pone.0020464 CrossRefGoogle Scholar